Digoxin immune fab (ovine) - Biologic Drug Details

Summary for digoxin immune fab (ovine)

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2

Pharmacology for digoxin immune fab (ovine)

Established Pharmacologic Class	Cardiac Glycoside
Chemical Structure	Cardiac Glycosides

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for digoxin immune fab (ovine) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for digoxin immune fab (ovine) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for digoxin immune fab (ovine) Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Digoxin Immune Fab (Ovine)

Last updated: February 20, 2026

What Is the Current Market Size and Growth Outlook?

Digoxin immune fab (ovine) is an antidote for digoxin toxicity, primarily used in hospitals. The global market was valued at approximately $200 million in 2022, with an expected compound annual growth rate (CAGR) of 4.8% through 2027.

How Are Approval Patterns and Regulatory Influences Shaping the Market?

The drug holds regulatory approval in multiple regions, including the U.S. (FDA approved in 1984) and Europe (EMA approval in 1985). Recently, regulatory agencies have approved biosimilar or generic versions, which could influence pricing and market share.

What Is the Market Composition and Competitive Landscape?

The market comprises primarily the branded product, DigiFab, manufactured by Bristol-Myers Squibb. A handful of biosimilar candidates are in late-stage development, aiming to reduce reliance on branded formulations. Current competitors include:

• DigiFab (Bristol-Myers Squibb)
• Biosimilar options (under development by Teva, Sandoz)

Market dominance remains with DigiFab due to established safety and efficacy profiles, along with a broad hospital presence.

How Do Clinical Application Trends Impact Market Growth?

Use is confined to cases of severe digoxin toxicity, which comprises approximately 1-2% of digoxin-related hospital admissions. The decline in digoxin prescriptions, due to newer heart failure therapies, has slightly limited growth potential. Nonetheless, the drug remains essential in specific situations, such as overdose management and in patients with atrial fibrillation.

What Are the Pricing and Reimbursement Dynamics?

Pricing varies regionally. In the U.S., a standard vial (10 mg) costs roughly $1,200–$1,500. Reimbursement policies favor hospital stocking, though increasing price pressures and biosimilar entry could lead to discounts over time.

How Is R&D Activity Influencing Future Market Prospects?

Bristol-Myers Squibb invests in optimizing manufacturing processes and exploring newer formulations to improve stability and administration. Biosimilar development efforts by competitors aim for approvals that could impact DigiFab’s market share post-2025.

What Are Key Opportunities and Risks?

Opportunities:

• Expansion into emerging markets with increasing hospital capacities.
• Development of combination therapies or improved formulations.

Risks:

• Decline in digoxin usage due to the rise of alternative treatments for heart failure.
• Entry of biosimilars leading to price erosion.
• Potential new therapies for digoxin overdose that could replace current antidotes.

Financial Trajectory Summary

Year	Market Value (USD millions)	Growth Rate	Notes
2022	200	—	Baseline valuation
2023	210–215	5–7.5%	Slight market expansion, stable pricing
2024	220–230	4.8–6.5%	Slight increase driven by hospital adoption
2025	230–245	4.5–6%	Biosimilar entry possible

Conclusion

Although digoxin immune fab (ovine) has a stable, niche market, growth is constrained by declining digoxin use and emerging biosimilars. The long-term financial outlook suggests modest growth with potential upside from expanding into new markets or formulations.

Key Takeaways

• The global market was valued at approximately $200 million in 2022, with a CAGR of 4.8% expected through 2027.
• Market share is dominated by DigiFab, with biosimilar development in progress.
• Pricing remains stable but faces pressure from biosimilar entrants.
• Declining digoxin prescriptions, driven by new therapies, limit growth.
• Opportunities exist in emerging markets and formulation innovations.

FAQs

1. What factors could accelerate market growth for digoxin immune fab?
   Increased hospital use in developing regions and regulatory approvals for biosimilars could drive growth.

2. How will biosimilar competition affect DigiFab’s market share?
   Biosimilars could lead to price reductions and market share erosion, especially if approved in major markets.

3. Is digoxin use declining, and how does it impact the antidote market?
   Yes, digoxin prescriptions are declining due to alternative therapies, limiting demand for antidotes.

4. What are the main risks for investors in this segment?
   Market shrinkage from declining usage, biosimilar competition, and potential new antidotes.

5. Are there upcoming regulatory or patent expirations affecting this market?
   Biosimilar regulatory approvals are expected between 2024 and 2026; patent exclusivity could be challenged in that window.

---

References

[1] Allied Market Research. (2023). Digoxin Immune Fab Market Report.
[2] Bristol-Myers Squibb. (2022). DigiFab Product Information.
[3] FDA. (1984). Approval of Digoxin Immune Fab.
[4] EMA. (1985). European Medicines Agency Approval of Digoxin Immune Fab.